Anti-Protective protein/Cathepsin A (PPCA) antibody (ab79590)

Overview

  • Product name
    Anti-Protective protein/Cathepsin A (PPCA) antibody
    See all Protective protein/Cathepsin A (PPCA) primary antibodies
  • Description
    Rabbit polyclonal to Protective protein/Cathepsin A (PPCA)
  • Specificity
    Detects full length Protective protein/Cathepsin A (PPCA) and the fragment of activated Protective protein/Cathepsin A (PPCA) resulting from cleavage adjacent to Arg326.
  • Tested applications
    Suitable for: WB, ELISAmore details
  • Species reactivity
    Reacts with: Human
    Predicted to work with: Mouse
  • Immunogen

    Synthetic peptide (Human)

  • Positive control
    • Extracts from Jurkat or 293 cells.

Properties

Applications

Our Abpromise guarantee covers the use of ab79590 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/500 - 1/1000. Predicted molecular weight: 32 , 54 kDa.
ELISA 1/10000.

Target

  • Function
    Protective protein appears to be essential for both the activity of beta-galactosidase and neuraminidase, it associates with these enzymes and exerts a protective function necessary for their stability and activity. This protein is also a carboxypeptidase and can deamidate tachykinins.
  • Involvement in disease
    Defects in CTSA are the cause of galactosialidosis (GSL) [MIM:256540]. A lysosomal storage disease associated with a combined deficiency of beta-galactosidase and neuraminidase, secondary to a defect in cathepsin A. All patients have clinical manifestations typical of a lysosomal disorder, such as coarse facies, cherry red spots, vertebral changes, foam cells in the bone marrow, and vacuolated lymphocytes. Three phenotypic subtypes are recognized. The early infantile form is associated with fetal hydrops, edema, ascites, visceromegaly, skeletal dysplasia, and early death. The late infantile type is characterized by hepatosplenomegaly, growth retardation, cardiac involvement, and a normal or mildly affected mental state. The juvenile/adult form is characterized by myoclonus, ataxia, angiokeratoma, mental retardation, neurologic deterioration, absence of visceromegaly, and long survival.
  • Sequence similarities
    Belongs to the peptidase S10 family.
  • Cellular localization
    Lysosome.
  • Information by UniProt
  • Database links
  • Alternative names
    • beta galactosidase 2 antibody
    • BETA GALACTOSIDASE PROTECTIVE PROTEIN antibody
    • beta-galactosidase 2 antibody
    • beta-galactosidase protective protein antibody
    • betagalactosidase 2 antibody
    • Carboxypeptidase C antibody
    • Carboxypeptidase L antibody
    • carboxypeptidase Y-like kininase antibody
    • Cathepsin A antibody
    • Ctsa antibody
    • deamidase antibody
    • EC 3.4.16.5 antibody
    • Glactosialidosis antibody
    • GLB2 antibody
    • Goldberg Syndrome antibody
    • GSL antibody
    • lysosomal carboxypeptidase A antibody
    • Lysosomal protective protein 20 kDa chain antibody
    • Lysosomal protective protein antibody
    • Lysosomal protective protein deficiency antibody
    • NEURAMINIDASE BETA GALACTOSIDASE EXPRESSION; NGBE antibody
    • Neuraminidase deficiency with beta-galactosidase deficiency antibody
    • NGBE antibody
    • OTTHUMP00000031778 antibody
    • OTTHUMP00000031781 antibody
    • PPCA antibody
    • PPCA deficiency antibody
    • PPGB antibody
    • PPGB_HUMAN antibody
    • Protective protein cathepsin A antibody
    • Protective protein for beta galactosidase antibody
    • Protective protein for beta-galactosidase antibody
    • Protective protein/cathepsin A deficiency antibody
    • urinary kininase antibody
    see all

Images

  • All lanes : Anti-Protective protein/Cathepsin A (PPCA) antibody (ab79590) at 1/500 dilution

    Lane 1 : Extracts from Jurkat cells, treated with etoposide (25uM, 1hour)
    Lane 2 : Extracts from 293 cells, treated with etoposide (25uM, 1hour)
    Lane 3 : Extracts from 293 cells, treated with etoposide (25uM, 1hour) with Cl-peptide at 5 µg/ml

    Lysates/proteins at 25 µg per lane.


    Predicted band size : 32 , 54 kDa

References

This product has been referenced in:
  • Lee C  et al. NEU1 sialidase regulates the sialylation state of CD31 and disrupts CD31-driven capillary-like tube formation in human lung microvascular endothelia. J Biol Chem 289:9121-35 (2014). WB ; Human . Read more (PubMed: 24550400) »

See 1 Publication for this product

Customer reviews and Q&As

Thank you for contacting Abcam.

As we discussed on the phone, sandwich ELISA typically increases sensitivity 2-5 fold compared to a standard ELISA. The specific sensitivity of each depends on the signal amplification process for the particular...

Read More

Thank you for this additional information. It appears you are using this for a sandwich ELISA with the Santa Cruz antibody. Sandwich ELISA procedures can be difficult to optimize and tested match pair antibodies should be used. This ensures the antibod...

Read More

Thank you for contacting us.

As requested, I have included our ELISA protocols for your review. I have attached pdf files of our indirect ELISA protocol and troubleshooting guide and have placed links below for additional guides which you ...

Read More

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

Sign up